The EU Scientific Committee on Consumer Safety (SCCS) has published final SCCS opinions on acetophenone heliotropin, giving cosmetics manufacturers, importers and responsible persons a clearer scientific reference point for two fragrance ingredients. Acetophenone and heliotropin are aromatic compounds used in cosmetic products for their scent properties. Both were evaluated after concerns emerged about a potential classification as Reproductive Toxicity Category 1B under Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging (CLP).
For regulatory teams, the immediate question is how these opinions may influence future restrictions and which documentation should be reviewed now. EU methods for managing substances that may be classified as CMR in cosmetics often begin with an SCCS opinion, making these conclusions an early compliance indicator.
According to COSlaw’s report on the new SCCS final opinions on acetophenone and heliotropin, the European Commission is expected to take the conclusions into account in a future Omnibus Act addressing CMR substances in cosmetic products. This article summarises the core findings and outlines practical checks for businesses operating in the EU and UK.
Understanding the final SCCS opinions on acetophenone heliotropin
Acetophenone (CAS No. 98-86-2, EC No. 202-708-7) is chemically known as 1-phenylethanone. It is primarily used in cosmetics as a fragrance ingredient because of its sweet, floral scent. Acetophenone occurs naturally in various plant-derived materials and natural complex substances, such as essential oils, concretes, absolutes, gums and resinoids.
Heliotropin (CAS No. 120-57-0, EC No. 204-409-7), also known as piperonal, is naturally present in some essential oils but is predominantly produced synthetically. It is widely used as a fragrance ingredient in perfumes, lotions, creams, shampoos and deodorants.
The SCCS evaluation was triggered by concerns that both substances could be classified as Reproductive Toxicity Category 1B under the CLP Regulation. The opinions sit at the intersection of raw material documentation, cosmetic product safety reporting and regulatory monitoring.
Acetophenone: safety conclusion and practical limit
The SCCS concluded that acetophenone is safe when present in cosmetic products at concentrations up to 100 ppm, equivalent to 0.01%, for both adults and children aged three years and above. This conclusion takes into account aggregate exposure, meaning the assessment considered exposure from sources other than cosmetic products as well.
This gives manufacturers a clear numerical benchmark for product development and safety assessment. The same limit applies to adult products and products intended for children aged three years and above, but the opinion does not cover children below that age.
Interpreting the 100 ppm limit
For a finished cosmetic product, the relevant comparison is the concentration of acetophenone in the final formulation. Brands should check whether the level stays at or below 100 ppm, not simply whether acetophenone is present in a raw material.
Natural complex substances remain outside the scope
The SCCS clarified that natural complex substances were not assessed as part of the opinion. The safety conclusion therefore applies only to acetophenone present within such substances and does not amount to a safety assessment of the natural complex substances themselves.
This distinction matters for botanical brands and manufacturers using essential oils. A natural complex substance may be safe in its own right, but the SCCS opinion does not provide that assurance. The safety of the complex substance must still be supported separately.
Heliotropin: restricted fine fragrance use for adults
For heliotropin, the SCCS concluded that the substance is safe when used at concentrations up to 1.8% in fine fragrances intended for adults. The conclusion is expressly limited to this specific use, as defined by the mandate received by the Committee, and does not extend to lotions, creams, shampoos, deodorants, children’s products or other cosmetic categories. If manufacturers want such uses assessed, the European Commission would need to issue a new mandate for a separate SCCS evaluation.
Why the conclusion is limited to fine fragrances
The limitation reflects the scope of the assessment rather than a finding that other uses are unsafe. Relying on the SCCS opinion is currently appropriate only for adult fine fragrances within the specified limit. The 1.8% limit is not a general cosmetic limit; it is tied to the specific exposure conditions and product type evaluated under the mandate.
Applicant calculations and wider exposure
The SCCS noted that the applicant submitted margin of safety calculations for a wider range of cosmetic products, including products intended for children. According to those calculations, combined exposure from such uses would remain within acceptable safety margins. However, this does not change the formal opinion, because the mandate covered only the limited fine fragrance use.
Compliance implications for EU and UK cosmetics businesses
The opinions are EU-level documents, but they matter for any brand, importer or responsible person managing formulations across the EU and UK. EU safety conclusions often influence supplier specifications, safety data sheets and global brand standards.
Because the UK cosmetics market remains closely aligned with retained EU standards in many areas, EU scientific opinions can influence supplier documentation and brand policies even when a separate UK opinion has not been issued. Manufacturers should not assume that the UK regulator has formally adopted the same position. Monitoring both EU and UK developments remains the safest approach.
For companies that place products in both markets, the practical burden is likely to sit in reviewing fragrance compound declarations, verifying levels in finished formulations, and aligning documentation with the new SCCS reference points. The SCCS opinions on acetophenone heliotropin are not immediate legislative amendments, but they should be treated as early indicators of regulatory direction.
Reviewing fragrance compounds and botanical extracts
Because acetophenone can occur naturally in botanical extracts and fragrance components, companies should not assume that a product is affected only when the single substance is listed as an ingredient. Supplier documentation and analytical testing may be needed to identify the level of acetophenone in complex raw materials.
Heliotropin is more commonly a synthetic fragrance ingredient, but it can still be present through fragrance compounds at levels that need verification. In both cases, raw material transparency is the starting point for compliance.
Updating cosmetic product safety files
Safety assessors should record the SCCS conclusions in the relevant sections of the cosmetic product safety report, particularly where a product contains either substance. For heliotropin, the product category and target user group are critical: only adult fine fragrances up to 1.8% align with the current SCCS conclusion. For acetophenone, the 100 ppm limit applies across product types for adults and children aged three years and above.
Where a product falls outside those parameters, companies may need to revisit the formulation, seek alternative data, or prepare a justification that does not rely solely on the SCCS opinions. Specialist EU and UK cosmetic compliance support can help responsible persons and brand owners interpret the impact on product portfolios.
What responsible persons and safety assessors should check now
Although the SCCS opinions do not yet change the Cosmetics Regulation, they provide an up-to-date scientific benchmark. Practical checks include:
- Review fragrance raw materials and compound declarations for acetophenone and heliotropin.
- Ask suppliers whether botanical extracts, essential oils or fragrance blends may contain either substance.
- Use analytical testing where supplier documentation is incomplete or uncertain.
- Calculate the concentration of acetophenone in each finished cosmetic product and compare it with the 100 ppm limit.
- Confirm whether heliotropin is present only in adult fine fragrances at or below 1.8%.
- Document the ingredient source, purity and relevant exposure considerations in the cosmetic product safety report.
These steps are especially relevant for products that contain natural complex substances, because the SCCS did not assess those substances as a whole. The level of acetophenone within a botanical extract still needs to be understood, even if the extract itself has a long history of use.
For heliotropin, product category is decisive. If a brand uses heliotropin in a body lotion, shampoo, deodorant or children’s product, the current SCCS opinion cannot be cited as the sole safety basis. A responsible person should verify whether a separate risk assessment is available or whether reformulation is the more practical route.
What to monitor after the SCCS opinions on acetophenone heliotropin
The European Commission is expected to take the SCCS conclusions into account in the future Omnibus Act addressing CMR substances in cosmetic products. This does not mean an immediate amendment to the Cosmetics Regulation, but it is a strong signal that acetophenone and heliotropin may be subject to future restrictions or specific conditions.
Companies should monitor the Commission’s next steps, particularly any draft text for the Omnibus Act, updates to the Cosmetics Regulation annexes, and further mandates or opinions from the SCCS. Regulatory teams should also watch whether national authorities or UK bodies issue aligned guidance, and whether industry associations publish updated recommendations for fragrance ingredient documentation.
In the meantime, maintaining accurate supplier records, product formulations and safety assessments will make any future transition smoother. Early review is usually less costly than reformulation after a restriction has entered into force.
Monitor ingredient levels, update safety files, and treat the SCCS conclusions as early regulatory indicators for fragrance compliance.